Table of Contents
Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The five branded anti-TNF antibodies Humira, Remicade, Enbrel, Simponi and Cimzia together achieved global sales of US$ 34.4 bln (+12.9%) in the year 2014. While the first biosimilars of Humira, Remicade and Enbrel are already marketed in less regulated countries such as India and China, it is only in February of 2015 that a biosimilar TNF antibody has been launched in the European Union. The Marketing Authorization Applications of further two biosimilar TNF antibodies have been just been submitted to the European Medicines Agency and the clinical pipeline of is rather full.
The report includes a compilation of currently active R&D projects of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...
Summary The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture partnering ...
“Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin ...